A share price of Cyclerion Therapeutics Inc [CYCN] is currently trading at $1.8, down -7.69%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CYCN shares have gain 52.54% over the last week, with a monthly amount glided 7.14%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cyclerion Therapeutics Inc [NASDAQ: CYCN] stock has seen the most recent analyst activity on October 20, 2021, when Truist initiated its Buy rating and assigned the stock a price target of $14. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on September 24, 2021, and set its price target to $7. On June 03, 2019, Credit Suisse initiated with a Neutral rating.
Cyclerion Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.16 and $6.25. Cyclerion Therapeutics Inc [NASDAQ: CYCN] shares were valued at $1.8 at the most recent close of the market.
Analyzing the CYCN fundamentals
Trailing Twelve Months sales for Cyclerion Therapeutics Inc [NASDAQ:CYCN] were 2.85M which represents 351.03% growth. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -1.27%, Pretax Profit Margin comes in at -0.77%, and Net Profit Margin reading is -0.77%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.25 and Total Capital is -0.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.6033 points at the first support level, and at 1.4067 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9733, and for the 2nd resistance point, it is at 2.1467.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cyclerion Therapeutics Inc [NASDAQ:CYCN] is 5.78. As well, the Quick Ratio is 5.78, while the Cash Ratio is 5.21. Considering the valuation of this stock, the price to sales ratio is 2.48, the price to book ratio is 0.70.
